



N C RAJ & ASSOCIATES

Chartered Accountants
10, Community Centre No.2,
Ashok Vihar Phase-II,
Delhi – 110 052
Phone: +911145670059
Website: www.ncraj.com
Email: info@ncraj.com
Peer Review No.: 014034

Independent Auditor's Report on Restated Financial Statements

To,
The Board of Directors
Medicamen Organics Limited
10 Community Centre No 2
Ashok Vihar Phase II,
New Delhi – 110052.

Dear Sir(s),

We have examined the attached restated financial information of **Medicamen Organics Limited** (hereinafter referred to as "**the Company**") comprising the restated Standalone statement of assets and liabilities as at March 31, 2024, March 31, 2023, and 2022, restated Standalone statement of profit and loss and restated cash flow statement for the financial year/period ended on March 31, 2024, March 31, 2023, and 2022 and the summary statement of significant accounting policies and other explanatory information (collectively referred to as the "**restated financial information**" or "**Restated Financial Statements**") annexed to this report and initialed by us for identification purposes. These Restated Financial Statements have been prepared by the management of the Company and approved by the board of directors at their meeting in connection with the proposed Initial Public Offering on EMERGE Platform ("**IPO**" or "**EMERGE IPO**") of National Stock Exchange of India Limited ("**NSE**") of the company.

- These restated summary statements have been prepared in accordance with the requirements of:
 - Section 26 of Part – I of Chapter III of Companies Act, 2013 (the "**Act**") read with Companies (Prospectus and Allotment of Securities) Rules 2014.
 - The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 ("**ICDR Regulations**") and related amendments / clarifications from time to time issued by the Securities and Exchange Board of India ("**SEBI**").
 - The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India ("**Guidance Note**")
- The Company's Board of Directors is responsible for the preparation of the Restated Financial Statements for inclusion in the Draft Red-Herring Prospectus/ Red-Herring Prospectus/ Prospectus ("**Offer Document**") to be filed with Securities and Exchange Board of India ("**SEBI**"), NSE and Registrar of Companies (Delhi) in connection with the proposed IPO. The Restated Financial Statements have been prepared by the management of the Company on the basis of preparation stated in Annexure IV to the Restated Financial Statements. The responsibility of the board of directors of the Company includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Financial Statements. The board of directors are also responsible for identifying and ensuring that the Company complies with the Act, ICDR Regulations and the Guidance Note.



3. We have examined such Restated Financial Statements taking into consideration:
- (i) The terms of reference and terms of our engagement letter requesting us to carry out the assignment, in connection with the proposed EMERGE IPO;
 - (ii) The Guidance Note also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI;
 - (iii) Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Restated Financial Statements;
 - (iv) The requirements of Section 26 of the Act and the ICDR Regulations. Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the IPO.
4. The Restated Financial Statements of the Company have been compiled by the management from audited financial statements for the year ended on March 31, 2024, March 31, 2023, and 2022.
5. Audit for the financial period ended March 31, 2024 was audited by us vide our report dt. 16-05-2024. Audit for the financial year ended March 31, 2023, and March 31, 2022 was conducted by Ashok Sharma & Associates vide report dt. September 7, 2023, and September 3, 2022 respectively. There are no audit qualifications in the audit reports issued by previous auditors and which would require adjustments in the Restated Financial Statements of the Company. The financial report included for these period/years is based solely on the report submitted by him.
6. Based on our examination and according to information and explanations given to us, we are of the opinion that the Restated Financial Statements:
- a) Have been prepared after incorporating adjustments for the changes in accounting policies, material errors and regrouping / reclassifications retrospectively in the financial year/period ended March 31, 2024, March 31, 2023, and 2022.
 - b) do not require any adjustment for modification as there is no modification in the underlying audit reports;
 - c) have no extra-ordinary items that need to be disclosed separately in the accounts and requiring adjustments.
 - d) have been prepared in accordance with the Act, ICDR Regulations and Guidance Note.
7. In accordance with the requirements of the Act including the rules made there under, ICDR Regulations, Guidance Note and engagement letter, we report that:



- a) The “**restated Standalone statement of asset and liabilities**” of the Company as at March 31, 2024, March 31, 2023, and 2022 examined by us, as set out in **Annexure I** to this report read with significant accounting policies in **Annexure IV** has been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to the restated summary statements to this report.
- b) The “**restated Standalone statement of profit and loss**” of the Company for the financial year/period ended as at March 31, 2024, March 31, 2023, and 2022 examined by us, as set out in **Annexure II** to this report read with significant accounting policies in **Annexure IV** has been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to the restated summary statements to this report.
- c) The “**restated Standalone statement of cash flows**” of the Company for the financial year/period ended as at March 31, 2024, March 31, 2023, 2022 examined by us, as set out in **Annexure III** to this report read with significant accounting policies in **Annexure IV** has been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in notes to restated summary statements to this report.
- d) The company has not specified the capitalization date for its building, resulting in inaccurate accounting for building depreciation.
- e) The Company has mentioned in the Note-1 to Annexure-XLI of the restated financial statements that:
“The Company has not accounted for interest provisions as per MSMED Act, 2006 as the company has made payments to MSME Vendors exceeding the contractual time-limit as per MSMED Act, 2006”.
8. We have also examined the following other financial information relating to the Company prepared by the management and as approved by the board of directors of the Company and annexed to this report relating to the Company for the financial year/period ended as at March 31, 2024, March 31, 2023, and 2022, proposed to be included in the Offer Document.

Annexure to Restated Financial Statements of the Company: -

- I. Summary statement of assets and liabilities, as restated as appearing in ANNEXURE I;
- II. Summary statement of profit and loss, as restated as appearing in ANNEXURE II;
- III. Summary statement of cash flows as restated as appearing in ANNEXURE III;
- IV. Corporate Information, Significant accounting policies as restated and Notes to reconciliation of restated profits and net worth as appearing in ANNEXURE IV;
- V. Details of share capital as restated as appearing in ANNEXURE V to this report;
- VI. Details of reserves and surplus as restated as appearing in ANNEXURE VI to this report;
- VII. Details of long-term borrowings as restated as appearing in ANNEXURE VII to this report;
- VIII. Details of deferred tax Liabilities (net) as appearing in ANNEXURE VIII to this report;
- IX. Details of long-term provisions as restated as appearing in ANNEXURE IX to this report;



- X. Details of short-term borrowings as restated as appearing in ANNEXURE X to this report;
- XI. Details of trade payables as restated as appearing in ANNEXURE XI to this report;
- XII. Details of other current liabilities as restated as appearing in ANNEXURE XII to this report;
- XIII. Details of short-term provisions as restated as appearing in ANNEXURE XIII to this report;
- XIV. Details of property, plant & equipment and intangible assets as appearing in ANNEXURE XIV to this report;
- XV. Details of other Long – Term Loans & Advances as restated as appearing in ANNEXURE XV to this report;
- XVI. Details of other non-current assets as restated as appearing in ANNEXURE XVI to this report;
- XVII. Details of inventories as restated as appearing in ANNEXURE XVII to this report;
- XVIII. Details of trade receivables as restated as appearing in ANNEXURE XVIII to this report;
- XIX. Details of cash and cash equivalents as restated as appearing in ANNEXURE XIX to this report;
- XX. Details of short-term loans and advances as restated as appearing in ANNEXURE XX to this report;
- XXI. Details of revenue from operations as restated as appearing in ANNEXURE XXI to this report;
- XXII. Details of other income as restated as appearing in ANNEXURE XXII to this report;
- XXIII. Details of cost of material consumed as restated as appearing in ANNEXURE XXIII to this report;
- XXIV. Details of direct expenses as restated as appearing in ANNEXURE XXIV to this report;
- XXV. Details of changes in inventories of Finished Goods & Work-in-Progress as restated as appearing in ANNEXURE XXV to this report.
- XXVI. Details of employee benefit expenses as restated as appearing in ANNEXURE XXVI to this report;
- XXVII. Details of finance costs as restated as appearing in ANNEXURE XXVII to this report;
- XXVIII. Details of depreciation and amortization expense as restated as appearing in ANNEXURE XXVIII to this report;
- XXIX. Details of other expenses as restated as appearing in ANNEXURE XXIX to this report;
- XXX. Details of bifurcative other income as restated as appearing in ANNEXURE XXX to this report;
- XXXI. Ageing of trade payables as restated as appearing in ANNEXURE XXXI to this report;
- XXXII. Ageing of trade receivables as restated as appearing in ANNEXURE XXXII to this report;
- XXXIII. Details of related party transactions as restated as appearing in ANNEXURE XXXIII to this report;
- XXXIV. Disclosure under AS-15 as restated as appearing in ANNEXURE XXXIV to this report;
- XXXV. Summary of significant accounting ratios as restated as appearing in ANNEXURE XXXV to this report;
- XXXVI. Statement of tax shelters as restated as appearing in ANNEXURE XXXVI to this report;
- XXXVII. Details of contingent liabilities & commitment as restated as appearing in ANNEXURE XXXVII to this report;
- XXXVIII. Details of restated value of imports calculated on C.I.F. basis by the company during the financial year/period as appearing in ANNEXURE XXXVIII to this report;
- XXXIX. Details of expenditure in foreign currency during the financial year/period as restated as appearing in ANNEXURE XXXIX to this report;
- XL. Details of earnings in foreign exchange as restated as appearing in ANNEXURE XL to this report;



(Forming part of Report issued to M/s Medicamen Organics Limited having UDIN: 24088636BKARIO5579)

- XLI. Details of dues of small enterprises and micro enterprises as restated as restated as appearing in ANNEXURE XLI to this report;
 - XLII. Additional Regulatory Information as per Para Y of Schedule III to Companies Act, 2013 as restated as appearing in ANNEXURE XLII to this report;
 - XLIII. Capitalisation Statement as at March 31, 2024 as restated as appearing in ANNEXURE XLIII to this report;
9. The report should not in any way be construed as a re-issuance or re-dating of any of the previous audit reports issued by any other firm of Chartered Accountants nor should this report be construed as a new opinion on any of the financial statements referred to therein.
10. We have no responsibility to update our report for events and circumstances occurring after the date of the report.
11. Our report is intended solely for use of the board of directors for inclusion in the offer document to be filed with SEBI, NSE and Registrar of Companies (Delhi) in connection with the proposed EMERGE IPO. Our report should not be used, referred to or distributed for any other purpose except with our prior consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For N C RAJ & ASSOCIATES
Chartered Accountants
(FRN: 002249N)

SANJAY GARG

Partner

Mem. No. 088636

Date: 20-05-2024

Place: New Delhi

UDIN: 24088636BKARIO5579



Medicamen Organics Limited
CIN: U74899DL1995PLC066416

STATEMENT OF ASSETS AND LIABILITIES AS RESTATED

ANNEXURE - I
(₹ In Lakhs)

Sr. No.	Particulars	Annexure No.	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
1)	EQUITY AND LIABILITIES				
	<u>Shareholders Funds</u>				
	a. Share Capital	V	860.00	600.00	600.00
	b. Reserves & Surplus	VI	658.40	297.99	201.06
2)	<u>Non - Current Liabilities</u>				
	a. Long-term Borrowings	VII	16.14	32.63	64.11
	b. Deferred tax Liabilities	VIII	118.54	116.49	111.40
	c. Long-term Provisions	IX	21.47	21.61	22.99
3)	<u>Current Liabilities</u>				
	a. Short Term Borrowings	X	1,249.51	1,146.87	960.46
	b. Trade Payables	XI			
	- Due to Micro and Small Enterprises		117.29	125.98	52.24
	- Due to Others		590.67	773.88	678.67
	c. Other Current liabilities	XII	105.93	97.28	44.74
	d. Short Term Provisions	XIII	120.12	45.84	18.12
TOTAL			3,858.07	3,258.57	2,753.79
1)	ASSETS				
	<u>Non Current Assets</u>				
	a. Property, Plant & Equipment and Intangible Assets	XIV			
	- Property, Plant & Equipment		1,033.91	1,085.65	1,127.67
	- Intangible Assets		1.01	1.20	1.40
	- Capital Work-in-Progress		14.63	-	-
	b. Long-term Loans & Advances	XV	46.58	46.58	46.58
	c. Other Non-current assets	XVI	30.72	38.55	35.33
2)	<u>Current Assets</u>				
	a. Inventories	XVII	614.26	613.90	472.18
	b. Trade Receivables	XVIII	1,670.00	1,076.82	624.54
	c. Cash and Bank Balance	XIX	55.30	52.82	43.74
	d. Short term loan and advances	XX	391.66	343.05	402.35
TOTAL			3,858.07	3,258.57	2,753.79

See accompanying annexures forming part of the restated financial statements (Refer Annexure No. IV to XLIII)

As per our attached Report of Even Date
For N C RAJ & ASSOCIATES

Chartered Accountants

FRN : 002249N

DELHI

SANJAY GARG

(Partner)

Membership No.: 088636

UDIN : 24088636BKARIO5579

Place : New Delhi

Date: 20-05-2024

For and on behalf of the Board of Directors of Medicamen Organics Limited

Bal Krishna

Bal Krishna Director
(Managing Director)

DIN - 00032772

For Medicamen Organics Limited

Lalit Gupta

Lalit Gupta
(CFO)

C.F.O.

Ashutosh Gupta

Ashutosh Gupta Director
(Director)

DIN - 00039995

For Medicamen Organics Limited

Varsha Bansal

Varsha Bansal Company Secretary
(Company Secretary)

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

STATEMENT OF PROFIT AND LOSS AS RESTATED

ANNEXURE - II
(₹ In Lakhs)

Sr. No.	Particulars	Annexure No.	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
A	INCOME				
	Revenue from Operations	XXI	2,527.17	2,214.71	2,097.52
	Other Income	XXII	1.79	81.53	21.15
	Total Income (A)		2,528.96	2,296.24	2,118.67
B	EXPENDITURE				
	Cost of material consumed	XXIII	1,439.94	1,398.16	1,411.92
	Direct Expenses	XXIV	286.91	241.36	225.41
	Changes in inventories of Finished Goods & Work in Progress	XXV	(146.99)	(59.80)	(71.36)
	Employee benefits expense	XXVI	335.39	316.63	287.36
	Finance costs	XXVII	64.74	61.24	47.32
	Depreciation and amortization expense	XXVIII	71.94	71.16	68.01
	Other expenses	XXIX	138.15	131.52	124.49
	Total Expenses (B)		2,190.08	2,160.27	2,093.15
C	Profit before tax		338.88	135.97	25.52
D	Tax Expense:				
	(i) Current tax	XXXVI	96.42	33.95	3.98
	(ii) Deferred tax expenses/(credit)		2.05	5.09	13.75
	(iii) MAT Credit Entitlement		-	-	(2.35)
	Total Expenses (D)		98.47	39.04	15.38
E	Profit for the year (C-D)		240.41	96.93	10.14
F	Earnings per share (Face value of ₹ 10/- each):				
	i. Basic		3.18	1.62	0.17
	ii. Diluted		3.18	1.62	0.17

See accompanying annexures forming part of the restated financial statements (Refer Annexure No. IV to XLIII)

As per our attached Report of Even Date

For N C RAJ & ASSOCIATES

Chartered Accountants

FRN : 002249

DELHI

SANJAY GARG

(Partner)

Membership No.: 088636

UDIN : 24088636BKARIO5579

Place : New Delhi

Date: 20-05-2024

For and on behalf of the Board of Directors of Medicamen Organics Limited

Bal Krishna Gupta

(Managing Director)

DIN - 00032772

For Medicamen Organics Limited

Lalit Gupta

(CFO)

For Medicamen Organics Limited

Varsha Bansal

(Company Secretary)

For Medicamen Organics Limited

Varsha Bansal

(Company Secretary)

STATEMENT OF CASH FLOW AS RESTATED

Particulars	For the Year ended March 31 , 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
<u>Cash Flow From Operating Activities:</u>			
Net Profit before tax as per Profit And Loss A/c	338.88	135.97	25.52
Adjustments for:			
Finance Cost	64.74	61.24	47.32
Gratuity Provision	2.74	(0.96)	4.25
Amount Written Back	-	(79.10)	(18.82)
Amount Written off	10.11	-	-
Interest Income	(1.34)	(0.81)	(2.33)
Leave Encashment Provision	2.05	1.65	1.53
Loss (Profit) on sale of fixed assets	-	-	-
Depreciation and Amortisation Expense	71.94	71.16	68.01
Operating Profit Before Working Capital Changes	489.12	189.15	125.48
Adjusted for (Increase) Decrease in operating assets			
Loans and advances	(48.61)	59.30	(37.41)
Inventories	(0.36)	(141.72)	(206.09)
Trade Receivables	(603.29)	(452.28)	128.37
Other Assets (Including Other Bank Balances)	4.61	(5.11)	(1.37)
Adjusted for Increase (Decrease) in operating liabilities:			
Trade Payables	(191.90)	248.05	48.13
Other Current Liabilities & Provisions	2.89	49.03	(46.83)
Cash Generated From Operations Before Extra-Ordinary Items	(347.54)	(53.58)	10.28
Net Income Tax paid/ refunded	(21.31)	(4.79)	(6.54)
Net Cash Flow from/(used in) Operating Activities: (A)	(368.85)	(58.37)	3.74
<u>Cash Flow from Investing Activities:</u>			
Purchase of property, plant & equipment and intangible assets (including CWIP)	(34.64)	(28.94)	(61.64)
Sale of property, plant & equipment	-	-	-
Interest Income Received	1.34	0.81	2.33
Net Cash Flow from/(used in) Investing Activities: (B)	(33.30)	(28.13)	(59.31)
<u>Cash Flow from Financing Activities:</u>			
Issue of Shares	60.00	-	-
Securities Premium	120.00	-	-
Proceeds (Repayment) of Borrowings	286.15	154.93	65.60
Finance Cost Paid	(64.74)	(61.24)	(47.32)
Net Cash Flow from/(used in) Financing Activities: (C)	401.41	93.69	18.28
Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	(0.74)	7.19	(37.29)
Cash & Cash Equivalents As At Beginning of the Year	44.06	36.87	74.16
Cash & Cash Equivalents As At End of the Year	43.32	44.06	36.87

Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE IV: CORPORATE INFORMATION, SIGNIFICANT ACCOUNTING POLICIES, RECONCILIATION OF NET PROFIT/(LOSS) AND RECONCILIATION OF NETWORTH

1. CORPORATE INFORMATION

Medicamen Organics Limited, originally incorporated on March 15, 1995, under the Companies Act, 1956, operated under the name "Panchdeep Pharmaceuticals Limited." Subsequently, on November 14, 1995, the company underwent a name change and became known as "Medicamen Organics Limited."

The corporate identification number of the company is U74899DL1995PLC066416.

The company is engaged in the business of manufacturing & trading of medicines, pharmaceutical formulations, remedies, vaccines and other biological product. The company is selling its product in India and outside India.

2. SIGNIFICANT ACCOUNTING POLICIES

2.01 BASIS OF ACCOUNTING AND PREPARATION OF FINANCIAL STATEMENTS

The restated summary statement of assets and liabilities of the Company as at March 31, 2024, March 31, 2023 and March 31, 2022 and the related restated summary statement of profits and loss and cash flows for the year/period ended March 31, 2024, March 31, 2023 and March 31, 2022 (herein collectively referred to as ("Restated Summary Statements")) have been compiled by the management from the audited Financial Statements of the Company for the year/period ended on March 31, 2024, March 31, 2023 and March 31, 2022 approved by the Board of Directors of the Company. Restated Summary Statements have been prepared to comply in all material respects with the provisions of Part I of Chapter III of the Companies Act, 2013 (the "Act") read with Companies (Prospectus and Allotment of Securities) Rules, 2014, Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations") issued by SEBI and Guidance note on Reports in Companies Prospectuses (Revised 2019) ("Guidance Note"). Restated Summary Statements have been prepared specifically for inclusion in the offer document to be filed by the Company with the NSE in connection with its proposed SME IPO. The Company's management has recast the Financial Statements in the form required by Schedule III of the Companies Act, 2013 for the purpose of restated Summary Statements.

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013 and the relevant provisions of the Companies Act, 2013 ("the 2013 Act"), as applicable. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

Accounting policies not specifically referred to otherwise are consistent and in consonance with generally accepted accounting principles in India.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in Schedule III to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has determined its operating cycle as twelve months for the purpose of current – non-current classification of assets and liabilities.

2.02 USE OF ESTIMATES

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.

2.03 PROPERTY, PLANT & EQUIPMENT AND INTANGIBLE ASSETS

(i) Property, Plant & Equipment


All Property, Plant & Equipment are recorded at cost including taxes, duties, freight and other incidental expenses incurred in relation to their acquisition and bringing the asset to its intended use.

(ii) Intangible Assets


Intangible Assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any.

For MEDICAMEN ORGANICS LTD.


Director


Director

For Medicamen Organics Limited


C.F.O.



For Medicamen Organics Limited


Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE IV: CORPORATE INFORMATION, SIGNIFICANT ACCOUNTING POLICIES, RECONCILIATION OF NET PROFIT(LOSS) AND RECONCILIATION OF NETWORTH

2.04 DEPRECIATION / AMORTISATION

Depreciation on fixed assets is calculated on a Straight Line method using the rates arrived at based on the useful lives estimated by the management, or those prescribed under the Schedule II to the Companies Act, 2013. Individual assets cost of which doesn't exceed Rs. 5,000/- each are depreciated in full in the year of purchase.

Intangible assets including internally developed intangible assets are amortised over the year for which the company expects the benefits to accrue. Intangible assets are amortized on straight line method basis over 10 years in pursuance of provisions of AS-26.

2.05 INVENTORIES

Inventory including raw materials, packing materials, Stores and Spares, Work-in-progress & finished goods are valued at lower of cost and net realizable value. Cost includes apportionment of labour and manufacturing overheads and other costs incurred in bringing the inventories to their present location, wherever applicable.

In determining the cost, the first-in-first-out method of valuation is used.

2.06 IMPAIRMENT OF ASSETS

An asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. Recoverable amount is the higher of an asset's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of the asset and from its disposal at the end of its useful life. Net selling price is the amount obtainable from sale of the asset in an arm's length transaction between knowledgeable, willing parties, less the costs of disposal. An impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting periods is reversed if there has been a change in the estimate of the recoverable value.

2.07 INVESTMENTS:

Non-current investments are carried at cost less any other-than-temporary diminution in value, determined on the specific identification basis.

Profit or loss on sale of investments is determined as the difference between the sale price and carrying value of investment, determined individually for each investment. Cost of investments sold is arrived using average method.

2.08 FOREIGN CURRENCY TRANSLATIONS

Income and expense in foreign currencies are converted at exchange rates prevailing on the date of the transaction. Any income or expense on account of exchange difference either on settlement or on translation at the balance sheet date is recognized in Profit & Loss Account in the year in which it arises.

2.09 BORROWING COSTS

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are recognised in Statement of Profit and Loss in the period in which they are incurred.

2.10 PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS

Provision involving substantial degree of estimation in measurement is recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent liabilities are not recognized but are disclosed in the notes. Contingent assets are neither recognized nor disclosed in the financial statements.

For MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Varsha Bansal
Company Secretary



Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE IV: CORPORATE INFORMATION, SIGNIFICANT ACCOUNTING POLICIES, RECONCILIATION OF NET PROFIT/(LOSS) AND RECONCILIATION OF NETWORTH

2.11 REVENUE RECOGNITION

Revenue is Recognised only when significant risk and rewards of ownership has been transferred to the buyer and it can be reliably measured and its reasonable to expect ultimate collection of it. Gross sales are of net trade discount, rebates, sales taxes and excise duties. Revenue from services is recognized, when services have been performed as per terms of contract, amount can be measured and there is no significant uncertainty as to collection.

The Company adopts accrual concepts in preparation of accounts. Claims /Refunds not ascertainable with reasonable certainty are accounted for on final settlement.

2.12 OTHER INCOME

Interest Income on fixed deposit is recognized on time proportion basis. Other Income is accounted for when right to receive such income is established.

2.13 TAXES ON INCOME

Income taxes are accounted for in accordance with Accounting Standard (AS-22) – “Accounting for taxes on income”, notified under Companies (Accounting Standard) Rules, 2014. Income tax comprises of both current and deferred tax.

Current tax is measured on the basis of estimated taxable income and tax credits computed in accordance with the provisions of the Income Tax Act, 1961.

The tax effect of the timing differences that result between taxable income and accounting income and are capable of reversal in one or more subsequent periods are recorded as a deferred tax asset or deferred tax liability. They are measured using substantially enacted tax rates and tax regulations as of the Balance Sheet date.

Deferred tax assets arising mainly on account of brought forward losses and unabsorbed depreciation under tax laws, are recognized, only if there is virtual certainty of its realization, supported by convincing evidence. Deferred tax assets on account of other timing differences are recognized only to the extent there is a reasonable certainty of its realization.

2.14 CASH AND BANK BALANCES

Cash and cash equivalents comprises Cash-in-hand, Current Accounts, Fixed Deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value. Other Bank Balances are short-term balance (with original maturity is more than three months but less than twelve months).

2.15 EARNINGS PER SHARE

Basic earning per share is computed by dividing the profit/ (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity share outstanding during the year. Diluted earning per share is computed by dividing the profit/ (loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares.

2.16 EMPLOYEE BENEFITS

Defined Contribution Plan:

Contributions payable to the recognised provident fund, which is a defined contribution scheme, are charged to the statement of profit and loss.

Defined Benefit Plan:

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15 days salary payable for each completed year of service without any monetary limit. Vesting occurs upon completion of five years of service. Provision for gratuity has been made in the books as per actuarial valuation done as at the end of the year.

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

For Medicamen Organics Limited

[Signature]

CFO



For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE IV: CORPORATE INFORMATION, SIGNIFICANT ACCOUNTING POLICIES, RECONCILIATION OF NET PROFIT/(LOSS) AND RECONCILIATION OF NETWORK

2.17 SEGMENT REPORTING

The accounting policies adopted for segment reporting are in line with the accounting policies of the Company. Segment revenue, segment expenses, segment assets and segment liabilities have been identified to segments on the basis of their relationship to the operating activities of the segment. Inter-segment revenue is accounted on the basis of transactions which are primarily determined based on market / fair value factors. Revenue and expenses have been identified to segments on the basis of their relationship to the operating activities of the segment. Revenue, expenses, assets and liabilities which relate to the Company as a whole and are not allocable to segments on reasonable basis have been included under "unallocated revenue / expenses / assets / liabilities".

For MEDICAMEN ORGANICS LTD.



Director


Director



For Medicamen Organics Limited



C.F.O.

For Medicamen Organics Limited


Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE IV: CORPORATE INFORMATION, SIGNIFICANT ACCOUNTING POLICIES, RECONCILIATION OF NET PROFIT/(LOSS) AND RECONCILIATION OF NETWORTH

3. NOTES ON RECONCILIATION OF RESTATED PROFITS

(₹ in Lakhs)

Particulars	For the Year ended March 31 , 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Net Profit/(Loss) after Tax as per Audited Profit & Loss Account	262.43	125.25	7.83
Adjustments for:			
Interest On FD	-	(0.17)	0.16
Depreciation and Amortization Expense	-	8.86	12.72
Profit on sale of Fixed Asset	-	-	-
Reversal of (Asset)/Liability	-	-	0.46
Prior Period Expense	(104.81)	-	-
Income tax expense	(0.22)	(32.95)	(2.98)
Deferred tax expense	83.01	(3.00)	(9.68)
MAT Credit Entitlement			2.35
Net Profit/ (Loss) After Tax as Restated	240.41	96.93	10.14

Explanatory notes to the above restatements to profits made in the audited Financial Statements of the Company for the respective years:

- a. Interest on FD :** The Company has booked excess interest on fixed deposits over the years which has now been restated.
- b. Depreciation and Amortization Expense:** The Company has inappropriately calculated depreciation using SLM method and useful life as per Schedule II of Companies Act, 2013 which has now been restated.
- c. Profit on sale of Fixed Asset:** The Company has sold Air conditioner in the year 2020-21 on which gain on sale of asset was booked with the higher amount the same has now been restated in the statement of profit and loss.
- d. Reversal of Asset/Liability :** The Company has not recognised asset or liability wrongly which has now been restated.
- e. Prior-period expenses:** The Company has recognised prior period expenses which has now been restated to respective years.
- f. Income Tax Expense:** The Company has inappropriately calculated income tax liability which has now been restated for restatement adjustment as above and provided for using tax rates related to the respective financial year as per Statement of tax shelters.
- g. Deferred Tax:** The Company has not calculated correctly the deferred tax impact which has now been restated including impact of restatement as above.
- h. MAT Credit Entitlement:** The Company has recognised the MAT credit during the previous years which has now been restated including impact of restatement as above.

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

For Medicamen Organics Limited
[Signature]

C.F.O.



For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE IV: CORPORATE INFORMATION, SIGNIFICANT ACCOUNTING POLICIES, RECONCILIATION OF NET PROFIT/(LOSS) AND RECONCILIATION OF NETWORTH

4. NOTES ON RECONCILIATION OF RESTATED NET-WORTH

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Networth as audited (a)	1,525.93	869.12	746.92
Adjustments for:			
Opening Balance of Adjustments	28.87	54.14	-
Reversal of depreciation expenses	-	-	83.42
Reversal of adjustment of provision for Tax	18.12	3.05	(3.05)
Income tax paid for earlier years	-	-	(1.80)
Reversal of Liability	-	-	(0.85)
Income Tax Expense not considered in earlier years	-	-	0.21
Deferred Tax Credit for previous years	-	-	(70.33)
Creation of MAT Credit Entitlement	(32.50)	-	44.23
Change in Profit/(Loss)	(22.02)	(28.32)	2.31
Closing Balance of Adjustments (b)	(7.53)	28.87	54.14
Networth as restated (a +b)	1,518.40	897.99	801.06

Explanatory notes to the above restatements to networth made in the audited Financial Statements of the Company for the respective years:

- a. Reversal of depreciation expenses :** The Company has inappropriately calculated depreciation using SLM method and useful life as per Schedule II of Companies Act, 2013 which has now been restated and debited to opening reserves for impact related to period on or before March 31, 2023.
- b. Reversal of adjustment of provision for tax:** The Company has inappropriately adjust the provision for tax from reserves & surplus which is now restated.
- c. Income Tax Paid for earlier years:** The Company has inappropriately calculate the income tax which is now restated.
- d. Reversal of liability :** The Company has wrongly took the liability in the books which is written off during the year.
- e. Income Tax expense not considered in earlier years :** The Company has wrongly calculate the income tax in the previous years which is now restated.
- f. Deferred Tax Credit for previous years :** The Company has not calculated correctly the deferred tax impact on WDV of property, plant & equipment which has now been restated.
- g. MAT Credit Entitlement:** The Company has recognised the MAT credit during the previous years which has now been restated.
- h. Change in Profit/(Loss) :** Refer Note 3 above.

5. ADJUSTMENTS HAVING NO IMPACT ON NETWORTH AND PROFIT:

a. Material Regrouping

Appropriate regroupings have been made in the Restated Summary Statements, wherever required, by a reclassification of the corresponding items of income, expenses, assets, liabilities and cash flows in order to bring them in line with the groupings as per the audited Financial Statements of the Company, prepared in accordance with Schedule III and the requirements of the Securities and Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018 (as amended).

For MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Company Secretary



RECONCILIATION OF RESTATED PROFIT:

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Networth as audited	1,525.93	869.12	746.92
Adjustments for:			
Opening Balance of Adjustments	28.87	54.14	
Reversal of depreciation expenses	-	-	83.42
Reversal of adjustment of provision for Tax	18.12	3.05	- 3.05
Income tax paid for earlier years	-	-	- 1.80
Reversal of Liability	-	-	- 0.85
Income Tax Expense not considered in earlier years	-	-	0.21
Creation of MAT Credit Entitlement	- 32.50	-	44.23
Deferred Tax Debit for previous years	-	-	- 70.33
Change in Profit/(Loss)	- 22.02	- 28.32	2.31
Closing Balance of Adjustments	- 7.53	28.87	54.14
Networth as restated	1,518.40	897.99	801.06

For MEDICAMEN ORGANICS LTD.

Director

Director



For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF SHARE CAPITAL AS RESTATED

ANNEXURE - V
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
EQUITY SHARE CAPITAL:			
AUTHORISED:			
Equity Shares of ₹ 10 each	1,400.00	800.00	600.00
ISSUED, SUBSCRIBED AND PAID UP			
Equity Shares of ₹ 10 each fully paid up	860.00	600.00	600.00
	860.00	600.00	600.00
TOTAL	860.00	600.00	600.00

Reconciliation of number of shares outstanding at the end of the year:

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Equity Shares at the beginning of the year	60,00,000	60,00,000	60,00,000
Add: Share Issued during the year	26,00,000	-	-
Total	86,00,000	60,00,000	60,00,000
Equity Shares at the end of the year	86,00,000	60,00,000	60,00,000

Note:

1) Terms/Rights attached to Equity Shares: The company has only one class of Equity Shares having a par value of ₹ 10/- per share. Each holder of Equity share is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity share will be entitled to receive remaining Assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the Share holders.

2) The equity shares are not repayable except in the case of a buy back, reduction of capital or winding up in terms of the provisions of the Companies Act, 2013.

3) Every member of the company holding equity shares has a right to attend the General Meeting of the Company and has a right to speak and on a show of hands, has one vote if he is present in person and on a poll shall have the right to vote in proportion to his share of the paid-up capital of the company.

Details of Shareholders holding more than 5% of the aggregate shares of the company:

Name of Shareholders	As at March 31, 2024	
	No. of Shares	% of Holding
Equity Share Holders		
Bal Kishan Gupta	61,02,650	70.96%
Ashutosh Gupta	5,87,400	6.83%
Shivani Chopra	6,00,000	6.98%

For MEDICAMEN ORGANICS LTD.

Director

Director



For Medicamen Organics Limited

For Medicamen Organics Limited

Company Secretary

C.F.O.

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

Details of Shareholders holding more than 5% of the aggregate shares of the company:

Name of Shareholders	As at March 31,2023	
	No. of Shares Held	% of Holding
Equity Share Holders		
Bal Kishan Gupta	44,86,650	74.78%
Ashutosh Gupta	6,19,500	10.33%
Shivani Chopra	6,00,000	10.00%

Details of Shareholders holding more than 5% of the aggregate shares of the company:

Name of Shareholders	As at March 31,2022	
	No. of Shares Held	% of Holding
Equity Share Holders		
Bal Kishan Gupta	44,86,650	74.78%
Ashutosh Gupta	6,19,500	10.33%
Shivani Chopra	6,00,000	10.00%

Details of equity shares held by promoters:

Name of Promoter	As at March 31,2024		% Change during the year
	No. of Shares Held	% of Holding	
Bal Kishan Gupta	61,02,650	70.96%	(3.82%)
Ashutosh Gupta	5,87,400	6.83%	(3.49%)

Details of equity shares held by promoters:

Name of Promoter	As at March 31,2023		% Change during the year
	No. of Shares Held	% of Holding	
Bal Kishan Gupta	44,86,650	74.78%	0.00%

Details of equity shares held by promoters:

Name of Promoter	As at March 31,2022		% Change during the year
	No. of Shares Held	% of Holding	
Bal Kishan Gupta	44,86,650	74.78%	0.00%

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director



For Medicamen Organics Limited
[Signature]
C.F.O.

For Medicamen Organics Limited
[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF RESERVE & SURPLUS AS RESTATED

ANNEXURE - VI
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
<u>Securities Premium</u>			
Opening Balance	91.44	91.44	91.44
Add: Received during the year	120.00	-	-
Closing Balance	211.44	91.44	91.44
<u>Balance in profit & Loss A/c</u>			
Opening Balance	206.55	109.62	44.60
Add : Net profit / (Loss) after Tax for the year	240.41	96.93	10.14
Add: Reversal of depreciation expenses	-	-	83.42
Less: Income tax paid for earlier years	-	-	(1.80)
Less: Reversal of (Asset)/Liability	-	-	(0.85)
Add: Income not considered in previous year	-	-	0.21
Less: Deferred Tax for previous years	-	-	(70.33)
Add: MAT Credit Entitlement	-	-	44.23
Closing Balance	446.96	206.55	109.62
TOTAL	658.40	297.99	201.06

DETAILS OF LONG TERM BORROWINGS AS RESTATED

ANNEXURE - VII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
<u>Secured</u>			
<u>Term Loan</u>			
- Banks	-	7.11	29.88
<u>Vehicle Loan</u>			
- Banks	16.14	25.52	34.23
TOTAL	16.14	32.63	64.11

(Refer Annexure for terms of security, repayment and other relevant details)

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

For Medicamen Organics Limited

[Signature]

C.F.O.



For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF DEFERRED TAX LIABILITY (NET) AS RESTATED

ANNEXURE - VIII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
<u>Deferred Tax Liability arising on account of:</u>			
-Difference of Depreciation as per Companies Act, 2013 and Income Tax Act, 1961	124.70	122.70	118.00
-Expenses disallowed under Income Tax Act, 1961	(6.16)	(6.21)	(6.60)
TOTAL	118.54	116.49	111.40

DETAILS OF LONG TERM PROVISIONS AS RESTATED

ANNEXURE - IX
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Provision for Gratuity	17.47	17.23	18.91
Provision for Leave Encashment	4.00	4.38	4.08
TOTAL	21.47	21.61	22.99

DETAILS OF SHORT TERM BORROWINGS AS RESTATED

ANNEXURE - X
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
<u>Secured</u>			
Bank Overdraft	125.27	98.70	36.57
Cash Credit	427.65	423.78	406.72
<u>Unsecured</u>			
Loan from Directors	680.10	592.91	475.07
Current maturities of long-term debt	16.49	31.48	42.10
TOTAL	1,249.51	1,146.87	960.46

(Refer Annexure for terms of security, repayment and other relevant details)

**Loan from Directors are interest-free and repayable on demand*

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

For Medicamen Organics Limited

[Signature]



C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF TRADE PAYABLES AS RESTATED

ANNEXURE - XI
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Due to Micro and Small Enterprises	117.29	125.98	52.24
Due to Others	590.67	773.88	678.67
TOTAL	707.96	899.86	730.91

(Refer Annexure - XXXI for ageing)

DETAILS OF OTHER CURRENT LIAIBILITES AS RESTATED

ANNEXURE - XII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Employee benefit payable	29.67	24.87	16.67
Director Remuneration Payable	5.53	-	1.59
Advances from Customers	33.54	43.69	8.32
Statutory Dues Payable (TDS, GST ,EPF, ESIC & TCS)	20.36	14.12	5.57
Audit fees payable	6.29	14.29	12.59
Rent payable	0.33	-	-
Expense payable	10.21	-	-
TOTAL	105.93	97.28	44.74

For MEDICAMEN ORGANICS LTD.

3ishu

Director

Shantanu Singh
Director

For Medicamen Organics Limited

Shantanu Singh

C.F.O.



For Medicamen Organics Limited

Vausha Bansal
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF SHORT TERM PROVISIONS AS RESTATED

ANNEXURE - XIII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Provision for Taxation (Net of Advance Tax, TDS and TCS)	111.97	36.86	7.70
Provision for Audit Fees	4.80	7.29	6.85
Provision for Gratuity	0.36	0.37	0.39
Provision for Bonus	2.69	0.99	2.83
Provision for Leave Encashment	0.30	0.33	0.35
TOTAL	120.12	45.84	18.12

DETAILS OF LONG-TERM LOANS & ADVANCES AS RESTATED

ANNEXURE - XV
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
MAT Credit Entitlement	46.58	46.58	46.58
TOTAL	46.58	46.58	46.58

DETAILS OF OTHER NON CURRENT ASSETS AS RESTATED

ANNEXURE - XVI
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Security Deposits	20.38	25.42	23.97
Fixed Deposit (having original maturity of more than 3 months and remaining maturity of more than 12 months)	2.47	2.10	0.33
Earnest Money Deposit	7.87	11.03	11.03
TOTAL	30.72	38.55	35.33

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director



For Medicamen Organics Limited

[Signature]

C.F.O.

For Medicamen Organics Limited
[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF INVENTORIES AS RESTATED

ANNEXURE - XVII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Raw Material	119.12	227.29	183.07
Packing Material	186.04	224.50	186.30
Work in progress	177.98	150.59	66.10
Finished goods	131.12	11.52	36.21
Stores & Spares	-	-	0.50
TOTAL	614.26	613.90	472.18

DETAILS OF TRADE RECEIVABLES AS RESTATED

ANNEXURE - XVIII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Unsecured, Considered Good			
Trade Receivable More than Six Months	292.94	206.41	175.05
Trade Receivable Less than Six Months	1,377.06	870.41	449.49
TOTAL	1,670.00	1,076.82	624.54

(Refer Annexure - XXXII for ageing)



For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

For Medicamen Organics Limited

[Signature]

C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DLI995PLC066416

DETAILS OF CASH & BANK BALANCE AS RESTATED

ANNEXURE - XIX
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
<i>a. Cash and Cash Equivalents</i>			
Cash-in-Hand	40.96	39.05	35.14
Bank Balance			
-In Current Accounts	2.36	5.01	1.73
<i>b. Other Bank Balances with Scheduled Bank</i>			
Fixed Deposit Receipts	11.98	8.76	6.87
(*having original maturity of more than 3 months and remaining maturity of Less than 12 months including given as collateral)			
TOTAL	55.30	52.82	43.74

DETAILS OF SHORT TERM LOAN AND ADVANCES AS RESTATED

ANNEXURE - XX
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Balance with Statutory Authorities	234.75	314.25	358.90
Advances to Suppliers	151.92	16.62	31.71
Prepaid Expenses	4.36	10.88	11.74
Advances to Staff	0.63	1.30	-
TOTAL	391.66	343.05	402.35

For Medicamen Organics Limited
Varsha Bansal
Company Secretary

For MEDICAMEN ORGANICS LTD.

Director
Director

Director
Director

For Medicamen Organics Limited

Director
Director



Medicamen Organics Limited
CIN: U74899DL1995PLC066416

RECONCILIATION OF RESTATED PROFIT:

(₹ In Lakhs)

Particulars	For the Year ended March 31 , 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Net Profit/(Loss) after Tax as per Audited Profit & Loss Account	262.43	125.25	7.83
Adjustments for:			
MAT Credit Entitlement	-	-	2.35
Interest On FD	-	0.17	0.16
Depreciation and Amortization Expense	0.00	8.86	12.72
Loss on sale of Fixed Asset	0.00	0.00	-
Reversal of (Asset)/Liability	0.00	0.00	0.46
Interest on Income Tax	0.00	-1.06	0.72
Income tax expense	-0.22	-32.95	2.98
Deferred tax expense	83.01	-3.00	9.68
Prior Period Expenses	-104.81	0.00	-
Net Profit/ (Loss) After Tax as Restated	240.41	96.93	10.14

For MEDICAMEN ORGANICS LTD.

Director

Director



For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Vaibha Bansal
 Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE- XIV
(₹ In Lakhs)

DETAILS OF PROPERTY, PLANT & EQUIPMENT AND INTANGIBLE ASSETS AS RESTATED

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	AS AT 01.04.2023	ADDITIONS	DEDUCTIONS	AS AT 31.03.2024	UPTO 01.04.2023	FOR THE YEAR	DEDUCTIONS	UPTO 31.03.2024	AS AT 31.03.2024	AS AT 31.03.2023
Property, Plant & Equipment										
Tangible Assets										
(a) Buildings	479.62	-	-	479.62	64.27	7.59	-	71.86	407.76	415.35
(b) Computer	14.28	0.39	-	14.67	12.64	0.52	-	13.16	1.51	1.64
(c) Plant and Machinery	89.70	-	-	89.70	36.98	4.98	-	41.96	47.74	52.72
(d) Furniture and Fixtures	29.36	-	-	29.36	13.91	2.78	-	16.69	12.67	15.45
(e) Office equipment	7.08	2.51	-	9.59	4.85	0.66	-	5.51	4.08	2.23
(f) Electrical Equipment	75.24	-	-	75.24	53.81	3.65	-	57.46	17.78	21.43
(g) Leasehold Land	53.71	-	-	53.71	-	-	-	-	53.71	53.71
(h) Motor Car	93.76	-	-	93.76	45.75	9.39	-	55.14	38.62	48.01
(i) Motor vehicle	0.02	-	-	0.02	0.02	-	-	0.02	-	-
(k) Plant and machinery factory	585.67	9.11	-	594.78	235.49	27.90	-	263.39	331.39	350.18
(l) A.C. Plant	157.65	-	-	157.65	73.11	7.27	-	80.38	77.27	84.54
(m) Lab equipment	80.37	8.00	-	88.37	39.98	7.01	-	46.99	41.38	40.39
Intangible Assets										
(a) Patent & Trademark	8.01	-	-	8.01	6.81	0.19	-	7.00	1.01	1.20
Capital Work-in-Progress										
(a) A.C. Plant	-	14.63	-	14.63	-	-	-	-	14.63	-
Total	1,674.47	34.64	-	1,709.11	587.62	71.94	-	659.56	1,049.55	1,086.85

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	AS AT 01.04.2022	ADDITIONS	DEDUCTIONS	AS AT 31.03.2023	UPTO 01.04.2022	FOR THE YEAR	DEDUCTIONS	UPTO 31.03.2023	AS AT 31.03.2023	AS AT 31.03.2022
Property, Plant & Equipment										
Tangible Assets										
(a) Buildings	478.36	1.26	-	479.62	56.70	7.57	-	64.27	415.35	421.66
(b) Computer	13.88	0.40	-	14.28	11.77	0.87	-	12.64	1.64	2.11
(c) Plant and Machinery	83.80	5.90	-	89.70	31.96	5.02	-	36.98	52.72	51.84
(d) Furniture and Fixtures	29.36	-	-	29.36	11.12	2.79	-	13.91	15.45	18.24
(e) Office equipment	6.56	0.52	-	7.08	4.28	0.57	-	4.85	2.23	2.28
(f) Electrical Equipment	71.22	4.02	-	75.24	50.44	3.37	-	53.81	21.43	20.78
(g) Leasehold Land	53.71	-	-	53.71	-	-	-	-	53.71	53.71
(h) Motor Car	91.97	1.79	-	93.76	36.37	9.38	-	45.75	48.01	55.60
(i) Motor vehicle	0.02	-	-	0.02	0.02	-	-	0.02	-	-
(k) Plant and machinery factory	571.57	14.10	-	585.67	208.08	27.41	-	235.49	350.18	363.49
(l) A.C. Plant	157.65	-	-	157.65	65.84	7.27	-	73.11	84.54	91.81
(m) Lab equipment	79.42	0.95	-	80.37	33.27	6.71	-	39.98	40.39	46.15
Intangible Assets										
(a) Patent & Trademark	8.01	-	-	8.01	6.61	0.20	-	6.81	1.20	1.40
Total	1,645.53	28.94	-	1,674.47	516.46	71.16	-	587.62	1,086.85	1,129.07

For MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Vausha Bansal
Company Secretary



Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE- XIV
(₹ In Lakhs)

DETAILS OF PROPERTY, PLANT & EQUIPMENT AND INTANGIBLE ASSETS AS RESTATED

Particulars	GROSS BLOCK			DEPRECIATION				NET BLOCK	
	AS AT 01.04.2021	ADDITIONS	DEDUCTIONS	AS AT 31.03.2022	UPTO 01.04.2021	FOR THE YEAR	DEDUCTIONS	UPTO 31.03.2022	AS AT 31.03.2022
Property, Plant & Equipment									
Tangible Assets									
(a) Buildings	478.36	-	-	478.36	49.13	7.57	-	56.70	421.66
(b) Computer	13.09	0.79	-	13.88	10.22	1.55	-	11.77	2.11
(c) Plant and Machinery	83.80	-	-	83.80	26.65	5.31	-	31.96	51.84
(d) Furniture and Fixtures	29.36	-	-	29.36	8.33	2.79	-	11.12	18.24
(e) Office equipment	5.68	0.88	-	6.56	3.90	0.38	-	4.28	2.28
(f) Electrical Equipment	71.22	-	-	71.22	47.03	3.41	-	50.44	20.78
(g) Leasehold Land	53.71	-	-	53.71	-	-	-	-	53.71
(h) Motor Car	42.66	49.31	-	91.97	30.26	6.11	-	36.37	55.60
(i) Motor vehicle	0.02	-	-	0.02	0.02	-	-	0.02	-
(j) Plant and machinery factory	565.49	6.08	-	571.57	181.14	26.94	-	208.08	363.49
(k) A.C. Plant	153.07	4.58	-	157.65	58.57	7.27	-	65.84	91.81
(m) Lab equipment	79.42	-	-	79.42	26.78	6.49	-	33.27	46.15
Intangible Assets									
(a) Patent & Trademark	8.01	-	-	8.01	6.42	0.19	-	6.61	1.40
Total	1,583.89	61.64	-	1,645.53	448.45	68.01	-	516.46	1,129.07
									1,135.44

For MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.



For Medicamen Organics Limited

Vaisha Bansal
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE FOR TERMS OF BORROWINGS AS RESTATED:

Name of Lender	Nature of Security	Repayment Terms	Sanction (₹ In Lakhs)	Rate of Interest	Tenure (Months)	No of O/S Installments	Instalment (₹)	Outstanding as on March 31, 2024 (₹ In Lakhs)	Outstanding as on March 31, 2023 (₹ In Lakhs)	Outstanding as on March 31, 2022 (₹ In lakhs)
Axis Bank Ltd (Working Capital) ²	Primary: Hypothecation of all existing & future Current asset and movable fixed assets of the company except vehicles financed by other banks / FI Collateral: 1 Equitable mortgage of leasehold Industrial properties as detailed below Plot no 60 sector 6A, industrial area IIE Ranipur, SIDCUL Dist. Handwar state of uttarakhand-249403 owned by medicamen organics limited 2 Plot no 61 sector 6A, industrial area IIE Ranipur, SIDCUL Dist. Handwar state of uttarakhand-249403 owned by medicamen organics limited Personal Guarantee- Bal Krishan Gupta Ashutosh Gupta	Repayment on Demand	310 / 410/425	Repo Rate+3.60% /Repo Rate+3.00%	12	NA	NA	427.65	423.78	406.72
Axis Bank Ltd (FD) ³	105 % Cash margin in the form of a FD of the bank, with bank's lien noted thereon. Lien shall be marked on the FD till such time as the obligation under the overdraft facility is fully satisfied. The FD shall be in the name of the Partners or family members of Partners	Repayment on Demand	99.75 / 90/127	FD R+ 1%	12	NA	NA	125.27	98.70	36.57

FOR MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited


C.F.O.

For Medicamen Organics Limited

Vansha Baniya
Company Secretary



Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE FOR TERMS OF BORROWINGS AS RESTATED:

Name of Lender	Nature of Security	Repayment Terms	Sanction (₹ In Lakhs)	Rate of Interest	Tenure (Months)	No of O/S Installments	Instalment (₹)	(₹ In Lakhs)		
								Outstanding as on March 31, 2024 (₹ In Lakhs)	Outstanding as on March 31, 2023 (₹ In Lakhs)	Outstanding as on March 31, 2022 (₹ In Lakhs)
Axis Bank Ltd ¹	<p>Primary: Hypothecation of all existing & future Current asset and movable fixed assets of the company except vehicles financed by other banks / FI</p> <p>Collateral: A) 1 Plot no 60 sector 6A, industrial area III Rampur, SIDCUL Dist. Handwar state of uttarakhand-249403 owned by medicamen organics limited 2 Plot no 61 sector 6A, industrial area III Rampur, SIDCUL Dist. Handwar state of uttarakhand-249403 owned by medicamen organics limited B) Extension of Hypothecation of entire Current assets & Movable Fixed assets of the company both present & Future except Vehicles financed by other bank/FI</p>	4 Years including 12 months of moratorium	64/62.22/36	Repo rate + 4.84% / Repo rate + 3.60% / Repo rate + 3.00%	36	10	1,77,777	7.11	29.88	51.94
Axis Bank Ltd	Car	60 Months	16.95	7.25%	60	42	33,763	10.83	13.97	16.95
Axis Bank Ltd	Car	60 Months	28.69	7.45%	60	34	57,421	14.69	20.26	25.43

¹ Loan Repayment Schedules are not available and hence, closing balances and current maturities are verified with statement of accounts.

² Earlier sanctioned amount was ₹ 310 Lakhs then increased to ₹ 410 Lakhs and then increased to ₹ 425 Lakhs.

³ Earlier sanctioned amount was ₹ 99.75 Lakhs and then reduced to ₹ 90 Lakhs.

FOR MEDICAMEN ORGANICS LTD.

Bill
Director

Alankar
Director

For Medicamen Organics Limited

Parvathy
C.F.O.

For Medicamen Organics Limited

Nasha Bangal
Company Secretary



Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF REVENUE FROM OPERATIONS AS RESTATED

ANNEXURE - XXI
(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Sale of Product and services	2,253.51	2,092.71	2,097.52
Sale of Services	273.66	122.00	-
TOTAL	2,527.17	2,214.71	2,097.52

DETAILS OF OTHER INCOME AS RESTATED


ANNEXURE - XXII
(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Interest on FD	1.34	0.81	2.33
Duty Drawback/RODTEP Received	0.28	0.66	-
Reimbursement of expenses	-	0.96	-
Provision for Gratuity Written Back	-	-	-
Foreign Exchange Rate Difference	0.17	-	-
Amount Written Back	-	79.10	18.82
TOTAL	1.79	81.53	21.15

DETAILS OF COST OF MATERIAL CONSUMED AS RESTATED

ANNEXURE - XXIII
(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Raw material Consumed			
Opening Stock	227.29	183.07	127.04
Add: Purchase During the year	955.65	1,099.75	710.55
Less : Transfer to other Branch	-	-	(18.73)
Less : Closing Stock	(119.12)	(227.29)	(183.07)
TOTAL	1,063.82	1,055.53	635.79
Packing Material and Stores & Spares Consumed			
Opening Stock	224.50	186.81	108.09
Add: Purchase During the year	337.66	380.32	854.85
Less : Closing Stock	(186.04)	(224.50)	(186.81)
TOTAL	376.12	342.63	776.13
TOTAL	1,439.94	1,398.16	1,411.92

For MEDICAMEN ORGANICS LTD.

Director



For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF DIRECT EXPENSES AS RESTATED

ANNEXURE - XXIV
(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Manufacturing expenses			
Labour Charges	117.11	87.33	85.30
Clearing and forwarding charges	-	-	0.96
Power, fuel & water	97.22	81.62	71.70
Consumable Stores	4.59	5.27	7.82
Freight & Cartage inwards	19.12	26.74	15.94
Analysis & testing Charges	16.25	23.00	18.67
Laboratories Expenses	7.50	6.13	6.59
Effluent treatment Expenses	2.40	2.63	2.31
Repairs and Maintenance			
-Building	8.81	0.26	0.82
-Machines & Electricals	10.67	5.21	11.74
-Others	3.24	3.17	3.56
TOTAL	286.91	241.36	225.41

CHNAGES IN INVENTORIES OF FINISHED GOODS & WORK IN PROGRESS

ANNEXURE - XXV
(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Opening Stock			
Finished Goods	11.52	36.21	7.25
Work in progress	150.59	66.10	23.70
Total	162.11	102.31	30.95
Closing Stock			
Finished Goods	131.12	11.52	36.21
Work in progress	177.98	150.59	66.10
Total	309.10	162.11	102.31
Stock Decreased/ (Increase) by	(146.99)	(59.80)	(71.36)

DETAILS OF EMPLOYEE BENEFIT EXPENSES AS RESTATED

ANNEXURE - XXVI
(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Salaries and Allowance	254.27	249.12	220.53
Director's Remuneration	33.24	29.49	36.19
EPF Employers Contribution	14.47	15.54	14.50
ESI Employers Contribution	1.85	2.11	1.98
Bonus & Ex-Gratia	5.18	1.58	3.07
Gratuity Expense	2.74	-	4.25
Leave Encashment Expenses	2.05	1.65	1.53
Workmen and Staff Welfare Expenses	21.59	17.14	5.31
TOTAL	335.39	316.63	287.36

FOR MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF FINANCE COST AS RESTATED

ANNEXURE - XXVII
(₹ In Lakhs)

Particulars	For the Year ended March 31 , 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Interest on Term loan	1.74	3.93	12.31
Interest on working capital	52.27	46.67	28.44
Interest on car loan	2.19	2.93	1.36
Bank Charges	2.36	4.66	3.75
Interest on delayed payment of taxes	0.79	1.99	0.74
Interest on Income Tax	3.96	1.06	0.72
Other Interest	1.43	-	-
TOTAL	64.74	61.24	47.32

DETAILS OF DEPRECIATION AND AMORTIZATION EXPENSE AS RESTATED

ANNEXURE - XXVIII
(₹ In Lakhs)

Particulars	For the Year ended March 31 , 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Depreciation and Amortization Expenses	71.94	71.16	68.01
TOTAL	71.94	71.16	68.01

For MEDICAMEN ORGANICS LTD.


Director


Director



For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited


Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF OTHER EXPENSES AS RESTATED

ANNEXURE - XXIX
(₹ In Lakhs)

Particulars	For the Year ended March 31 , 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Adminstration, selling & other expenses			
Legal and Professional Charges	11.15	11.23	10.23
Security Service Charges	25.98	23.35	21.20
Registration charges	1.68	1.89	2.49
Travelling & Conveyance	10.18	5.89	5.58
Fees and Subcription	9.58	7.01	5.34
Miscellaneous expenses	14.76	8.97	10.09
Donation	1.50	-	2.00
GST Late Fees	-	0.01	0.14
Pollution fees	-	2.70	-
Amount Written off	10.11	-	-
Rates & Taxes	0.24	0.38	0.35
Housekeeping Expenses	1.94	1.41	1.78
Communication Expenses	4.45	4.08	3.98
Printing and Stationery	5.30	4.40	3.86
Vehicle running Expenses	4.66	4.63	2.51
Distribution Expenses	1.07	9.51	2.59
Commission on Sale	15.28	24.11	36.84
Computer expenses	1.60	2.20	3.68
Office Expenses	1.69	2.05	1.90
Business Promotion expense	3.01	5.60	1.09
Foreign Exchange flutuation	-	1.42	0.09
Insurance Charges			
- Vehicles	1.11	1.59	1.08
- Stocks & Building	3.31	2.66	1.97
- Others	0.29	0.37	0.31
Rent	4.26	4.06	3.39
Audit Fees	5.00	2.00	2.00
Total	138.15	131.52	124.49

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director



For Medicamen Organics Limited

[Signature]

C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF OTHER INCOME AS RESTATED

ANNEXURE - XXX

(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022	Nature
Other Income	1.79	81.53	21.15	
Net Profit Before Tax as Restated	338.88	135.97	25.52	
Percentage	0.53%	59.96%	82.88%	

Source of Income

Interest Income on FD	1.34	0.81	2.33	Recurring and not related to Business Activity
Duty Drawback/RODTEP Received	0.28	0.66	-	Non-Recurring and related to Business Activity
Provision for Gratuity Written Back	-	0.96	-	Non-Recurring and not related to Business Activity
Amount Written off	-	79.10	18.82	Non-Recurring and not related to Business Activity
Foreign Exchange Fluctuation	0.17	-	-	Recurring and related to Business Activity
Total Other income	1.79	81.53	21.15	

For MEDICAMEN ORGANICS LTD

[Signature]
Director



For Medicamen Organics Limited
[Signature]

C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

AGEING OF TRADE PAYABLES AS RESTATED

ANNEXURE - XXXI
(₹ In Lakhs)

I. Ageing of Creditors as at March 31, 2024

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(a) MSME	114.58	2.42	0.02	0.27	117.29
(b) Others	461.42	100.35	22.19	6.71	590.67
(c) Disputed Dues - MSME	-	-	-	-	-
(d) Disputed Dues - Others	-	-	-	-	-
Total	576.00	102.77	22.21	6.98	707.96

II. Ageing of Creditors as at March 31, 2023

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(a) MSME	119.49	4.14	1.13	1.22	125.98
(b) Others	722.74	41.30	9.16	0.68	773.88
(c) Disputed Dues - MSME	-	-	-	-	-
(d) Disputed Dues - Others	-	-	-	-	-
Total	842.23	45.44	10.29	1.90	899.86

III. Ageing of Creditors as at March 31, 2022

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(a) MSME	49.88	1.13	1.23	-	52.24
(b) Others	584.89	88.58	4.78	0.42	678.67
(c) Disputed Dues - MSME	-	-	-	-	-
(d) Disputed Dues - Others	-	-	-	-	-
Total	634.77	89.71	6.01	0.42	730.91

For MEDICAMEN ORGANICS LTD

[Signature]
Director

[Signature]
Director



For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

AGEING OF TRADE RECEIVABLES AS RESTATED

ANNEXURE - XXXII
(₹ In Lakhs)

I. Ageing of Debtors as at March 31, 2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(a) Undisputed Trade receivables - considered good	1,377.06	9.42	158.12	74.28	7.98	1,626.86
(b) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-	-
(c) Disputed Trade Receivables - considered good	-	7.70	-	20.60	14.84	43.14
(d) Disputed Trade Receivables - considered doubtful	-	-	-	-	-	-
Total	1,377.06	17.12	158.12	94.88	22.82	1,670.00

II. Ageing of Debtors as at March 31, 2023

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(a) Undisputed Trade receivables - considered good	870.41	63.15	90.94	12.38	14.20	1,051.08
(b) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-	-
(c) Disputed Trade Receivables - considered good	-	4.44	12.32	8.98	-	25.74
(d) Disputed Trade Receivables - considered doubtful	-	-	-	-	-	-
Total	870.41	67.59	103.26	21.36	14.20	1,076.82

III. Ageing of Debtors as at March 31, 2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(a) Undisputed Trade receivables - considered good	449.49	51.07	98.91	11.56	13.51	624.54
(b) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-	-
(c) Disputed Trade Receivables - considered good	-	-	-	-	-	-
(d) Disputed Trade Receivables - considered doubtful	-	-	-	-	-	-
Total	449.49	51.07	98.91	11.56	13.51	624.54

For MEDICAMEN ORGANICS LTD.

Sighe
Director

Atul Singh
Director



For Medicamen Organics Limited

Atul Singh
C.F.O.

For Medicamen Organics Limited

Vaishali Bansal
Company Secretary

DETAILS OF RELATED PARTY TRANSACTION AS RESTATED

Name of Related Party	Nature of Relationship	Nature of Transaction	Amount of transaction during the year ended March 31, 2024	Amount outstanding as on March 31, 2023 (Payable)/ Receivable	Amount of transaction during the year ended March 31, 2023	Amount outstanding as on March 31, 2023 (Payable)/ Receivable	Amount of transaction during the year ended March 31, 2022	Amount outstanding as on March 31, 2022 (Payable)/ Receivable
Mr. Bal Krishan Gupta	Director	Remuneration Loan Taken Loan Repaid	15.58 571.35 490.53	- (657.60)	15.35 174.80 64.03	- (576.78)	13.41 83.74 78.44	- (466.01)
Mr. Ashutosh Gupta	Director	Remuneration Loan Taken Loan Repaid	7.19 10.95 5.70	- (3.25)	7.02 0.70 0.76	- -	7.47 9.47 7.06	- (0.06)
Mr. Shalesh hamohan gaur	Director	Remuneration Loan repaid -	10.47 -	-	7.12	-	8.25 0.48	-
H.C. (nukam chand) Sharma	Director	Loan taken Salaried -	- -	-	-	-	5.40 1.00	4.82
Ritu Gupta	Relative of director (Wife of BK. Gupta)	Loan repaid Loan taken	6.00 -	(2.30)	5.49 2.30	4.82 (2.30)	5.40 1.00	4.82
Redline Healthcare Partnership firm	Company in which director is Director	Sales of services Purchase of services Loan repaid	- 10.49 -	25.91 -	30.08 145.98 -	26.91 (134.92)	34.36 93.69 0.09	- (68.16)
Redline Healthcare pvt limited (unt a)	Company in which director is Director	Loan taken Interest Paid to party (cumulative under loan)	- 1.12	(14.95)	4.00 0.82	(13.83)	9.09	(9.00)
Jashal Pharma LLP (Unit II)	Company in which Sales of Services		39.09	1.40	6.54	3.38	14.99	4.43

* Note : All reimbursement closing balance payable showing debit balance are presented in loans & advances

For MEDICAMEN ORGANICS LTD.
Zeel
Director
Rajesh Kumar
Director

For Medicamen Organics Limited
afat
C.F.O.

For Medicamen Organics Limited
Vaishya Bawar
Company Secretary



Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DISCLOSURE UNDER AS-15 AS RESTATED

ANNEXURE - XXXIV

A. DEFINED CONTRIBUTION PLAN

Particulars	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Employers' Contribution to Provident Fund and ESIC	16.32	17.65	16.48

B. DEFINED BENEFIT OBLIGATION

1) Gratuity

The gratuity benefit payable to the employees of the Company is as per the provisions of the Payment of Gratuity Act, 1972, as amended. Under the gratuity plan, every employee who has completed at least 5 years of service gets gratuity on separation or at the time of superannuation calculated for equivalent to 15 days salary for each completed year of service calculated on last drawn basic salary. The Company does not have a funded plan for gratuity liability.

I. ASSUMPTIONS:	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Discount Rate	7.22%	7.36%	7.18%
Salary Escalation	5.50%	5.50%	5.50%
Withdrawal Rates	up to 30 Years: 3% p.a. 31 to 44 Years: 2% p.a. Above 44 Years: 1% p.a.	up to 30 Years: 3% p.a. 31 to 44 Years: 2% p.a. Above 44 Years: 1% p.a.	up to 30 Years: 3% p.a. 31 to 44 Years: 2% p.a. Above 44 Years: 1% p.a.
Mortality Table	Indian Assured Lives Mortality (2012-14) Ult.	Indian Assured Lives Mortality (2012-14) Ult.	Indian Assured Lives Mortality (2012-14) Ult.
Retirement Age	58 years	58 years	58 years

II. CHANGE IN THE PRESENT VALUE OF DEFINED BENEFIT OBLIGATION:	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Present Value of Benefit Obligation as at the beginning of the year	17.60	19.30	16.10
Current Service Cost	2.34	2.60	3.50
Interest Cost	1.30	1.39	1.10
(Benefit paid)	(2.51)	(0.74)	(1.05)
Actuarial (gains)/losses	(0.90)	(4.95)	(0.35)
Present value of benefit obligation as at the end of the year	17.83	17.60	19.30

III. ACTUARIAL GAINS/LOSSES:	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Actuarial (gains)/losses on obligation for the year	(0.90)	(4.95)	(0.35)
Actuarial (gains)/losses on asset for the year	-	-	-
Actuarial (gains)/losses recognized in income & expenses Statement	(0.90)	(4.95)	(0.35)

For MEDICAMEN ORGANICS LTD.

[Signature]

Director

[Signature]
Director



For Medicamen Organics Limited
[Signature]

CFO

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DISCLOSURE UNDER AS-15 AS RESTATED

ANNEXURE - XXXIV

IV. EXPENSES RECOGNISED	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Current service cost	2.34	2.60	3.50
Interest cost	1.30	1.39	1.10
Actuarial (gains)/losses	(0.90)	(4.95)	(0.35)
Expense charged to the Statement of Profit and Loss	2.74	(0.96)	4.25

V. BALANCE SHEET RECONCILIATION:	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Opening net liability	17.60	19.30	16.10
Expense as above	2.74	(0.96)	4.25
(Benefit paid)	(2.51)	(0.74)	(1.05)
Net liability/(asset) recognized in the balance sheet	17.83	17.60	19.30

VI. EXPERIENCE ADJUSTMENTS	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
On Plan Liability (Gains)/Losses	(1.17)	(4.56)	0.62

VII. The estimates of rate of salary increase considered in the actuarial valuation takes into account inflation, seniority, promotion and all other relevant factors including supply and demand in the employment market.

2) Leave Encashment:

I. ASSUMPTIONS:	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Discount Rate	7.22%	7.36%	7.18%
Salary Escalation	5.50%	5.50%	5.50%
Withdrawal Rates	up to 30 Years: 3% p.a. 31 to 44 Years: 2% p.a. Above 44 Years: 1% p.a.	up to 30 Years: 3% p.a. 31 to 44 Years: 2% p.a. Above 44 Years: 1% p.a.	up to 30 Years: 3% p.a. 31 to 44 Years: 2% p.a. Above 44 Years: 1% p.a.
Mortality Table	Indian Assured Lives Mortality (2012-14) Ult.	Indian Assured Lives Mortality (2012-14) Ult.	Indian Assured Lives Mortality (2012-14) Ult.
Retirement Age	58 years	58 years	58 years

II. CHANGE IN THE PRESENT VALUE OF DEFINED BENEFIT OBLIGATION:	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Present Value of Benefit Obligation as at the beginning of the year	4.71	4.44	4.11
Current Service Cost	0.76	0.92	1.12
Interest Cost	0.35	0.32	0.28
(Benefit paid)	(2.46)	(1.38)	(1.20)
Actuarial (gains)/losses	0.94	0.41	0.13
Present value of benefit obligation as at the end of the year	4.30	4.71	4.44

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

For Medicamen Organics Limited

[Signature]

C.F.O.



For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURE - XXXIV

DISCLOSURE UNDER AS-15 AS RESTATED

III. ACTUARIAL GAINS/LOSSES:	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Actuarial (gains)/losses on obligation for the year	0.94	0.41	0.13
Actuarial (gains)/losses on asset for the year	-	-	-
Actuarial (gains)/losses recognized in income & expenses Statement	0.94	0.41	0.13

IV. EXPENSES RECOGNISED	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Current service cost	0.76	0.92	1.12
Interest cost	0.35	0.32	0.28
Actuarial (gains)/losses	0.94	0.41	0.13
Expense charged to the Statement of Profit and Loss	2.05	1.65	1.53

V. BALANCE SHEET RECONCILIATION:	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
Opening net liability	4.71	4.45	4.12
Expense as above	2.05	1.65	1.53
(Benefit paid)	(2.46)	(1.38)	(1.20)
Net liability/(asset) recognized in the balance sheet	4.30	4.72	4.45

VI. EXPERIENCE ADJUSTMENTS	For the Year ended March 31, 2024 (₹ in Lakhs)	For the year ended March 31, 2023 (₹ in Lakhs)	For the year ended March 31, 2022 (₹ in Lakhs)
On Plan Liability (Gains)/Losses	0.88	0.52	0.35

VII. The estimates of rate of salary increase considered in the actuarial valuation takes into account inflation, seniority, promotion and all other relevant factors including supply and demand in the employment market.

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director



For Medicamen Organics Limited

[Signature]

C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

DETAILS OF ACCOUNTING RATIOS AS RESTATED

ANNEXURE - XXXV
(₹ In Lakhs, except per share data and ratios)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Restated Profit after Tax as per Profit & Loss Statement (A)	240.41	96.93	10.14
Tax Expense (B)	98.47	39.04	15.38
Depreciation and amortization expense (C)	71.94	71.16	68.01
Interest Cost (D)	64.74	61.24	47.32
Weighted Average Number of Equity Shares at the end of the Year (E)	75,62,842	60,00,000	60,00,000
Number of Equity Shares outstanding at the end of the Year (F)	86,00,000	60,00,000	60,00,000
Nominal Value per Equity share (₹) (G)	10.00	10.00	10.00
Restated Net Worth of Equity Share Holders as per Statement of Assets and Liabilities (H)	1,518.40	897.99	801.06
Current Assets (I)	2,731.22	2,086.59	1,542.81
Current Liabilities (J)	2,183.52	2,189.85	1,754.23
Earnings Per Share - Basic & Diluted¹ (₹)	3.18	1.62	0.17
Return on Net Worth¹ (%)	15.83%	10.79%	1.27%
Net Asset Value Per Share¹ (₹)	17.66	14.97	13.35
Current Ratio¹	1.25	0.95	0.88
Earning before Interest, Tax and Depreciation and Amortization¹ (EBITDA)	475.56	268.37	140.85

Notes -

1. Ratios have been calculated as below:

Earnings Per Share (₹) (EPS) : $\frac{A}{E}$

Return on Net Worth (%): $\frac{A}{H}$

Net Asset Value per equity share (₹): $\frac{H}{F}$

Current Ratio: $\frac{I}{J}$

Earning before Interest, Tax and Depreciation and Amortization (EBITDA): $A + (B+C+D)$

For MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.



For Medicamen Organics Limited

Company Secretary


Medicamen Organics Limited
CIN: U74899DL1995PLC066416

STATEMENT OF TAX SHELTERS

ANNEXURE - XXXVI
(₹ In Lakhs)

Particulars	For the Year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Profit before tax as per books (A)	338.88	135.97	25.52
Income Tax Rate* (%)	27.82%	27.82%	26.00%
MAT Rate* (%)	16.69%	16.69%	15.60%
Tax at notional rate on profits	94.28	37.83	6.64
Adjustments :			
Permanent Differences(B)			
<u>Expenses disallowed under Income Tax Act, 1961</u>			
- Late Fees on GST Return	-	0.01	0.14
- Interest on TDS & Income Tax	4.75	3.05	1.46
- Donation	1.50	-	2.00
<u>Disallowance under section 36</u>			
- EPF Employee Share	6.74	15.54	33.52
- ESI Employee Share	2.09	-	-
Total Permanent Differences(B)	15.08	18.60	37.12
Income considered separately (C)			
Interest Income	(1.34)	(0.81)	(2.33)
Total Income considered separately (C)	(1.34)	(0.81)	(2.33)
Timing Differences (D)			
Depreciation as per Companies Act, 2013	71.94	71.16	68.01
Depreciation as per Income Tax Act, 1961	(79.12)	(88.05)	(96.38)
Gratuity Provision	2.74	(0.96)	4.24
Gratuity Paid	(2.50)	(0.73)	(1.06)
Leave Encashment Provision	2.05	1.65	1.53
Leave Encashment Paid	(2.47)	(1.38)	(1.21)
Total Timing Differences (D)	(7.36)	(18.31)	(24.87)
Net Adjustments E = (B+C+D)	6.38	(0.52)	9.92
Tax expense / (saving) thereon	1.77	(0.14)	2.58
Income from Other Sources			
Interest Income	1.34	0.81	2.33
Income from Other Sources (E)	1.34	0.81	2.33
Set-off from Brought Forward Losses (F)			
Taxable Income/(Loss) as per Income Tax (A+E+F)	-	(14.24)	(31.49)
	346.60	122.02	6.28
Set-off from Brought Forward Losses for MAT (G)			
Taxable Income/(Loss) as per MAT (A+G)	-	-	-
Income Tax as returned/computed	338.88	135.97	25.52
Tax paid as per normal or MAT	96.42	33.95	3.98
	Normal	Normal	MAT

*The Company has not opted for income tax rates specified under section 115BAA of Income Tax Act, 1961.

For MEDICAMEN ORGANICS LTD.

Director



For Medicamen Organics Limited



C.F.O.

For Medicamen Organics Limited


Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

DETAILS OF CONTINGENT LIABILITIES & COMMITMENTS AS RESTATED

ANNEXURE - XXXVII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
I. Contingent Liabilities			
(a) claims against the company not acknowledged as debt;	13.27	13.27	13.27
(b) guarantees excluding financial guarantees; and	-	-	-
(c) other money for which the company is contingently liable	-	-	-
II. Commitments			
(a) estimated amount of contracts remaining to be executed on capital account and not provided for	-	-	-
(b) uncalled liability on shares and other investments partly paid	-	-	-
(c) other commitments	-	-	-

RESTATED VALUE OF IMPORTS CALCULATED ON C.I.F BASIS BY THE COMPANY DURING THE FINANCIAL YEAR IN RESPECT OF:

ANNEXURE - XXXVIII
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
	₹	₹	₹
(a) Raw Material	-	-	-
(b) Components and spare parts	-	-	-
(c) Capital goods	-	-	-



For MEDICAMEN ORGANICS LTD.

 Director

For Medicamen Organics Limited

 C.F.O.

For Medicamen Organics Limited

 Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

EXPENDITURE IN FOREIGN CURRENCY DURING THE FINANCIAL YEAR AS RESTATED :			
ANNEXURE - XXXIX (₹ In Lakhs)			
Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
	₹	₹	₹
(a) Royalty	-	-	-
(b) Know-How	-	-	-
(c) Professional and consultation fees	-	-	-
(d) Interest	-	-	-
(e) Purchase of Components and spare parts	-	-	-
(f) Others	-	-	-

EARNINGS IN FOREIGN EXCHANGE AS RESTATED:			
ANNEXURE - XL (₹ In Lakhs)			
Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
	₹	₹	₹
(a) Export of goods calculated on F.O.B. basis	13.98	52.41	-
(b) Royalty, know-how, professional and consultation fees	-	-	-
(c) Interest and dividend	-	-	-
(d) Other income	-	-	-

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director



For Medicamen Organics Limited

[Signature]

C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

DUES OF SMALL ENTERPRISES AND MICRO ENTERPRISES AS RESTATED

ANNEXURE - XLI
(₹ In Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
	₹	₹	₹
(a) Dues remaining unpaid to any supplier at the end of each accounting year			
-Principal	117.29	125.98	52.24
-Interest on the above	-	-	-
(b) the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	-	-	-
(c) the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;	-	-	-
(d) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	-	-	-

Note 1 :The Company has not accounted for interest provisions as per MSMED Act, 2006 as the company has made payments to MSME Vendors within contractual period which is exceeding the contractual time-limit as per MSMED Act, 2006.



OF MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Vaishali Bansal
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

ADDITIONAL REGULATORY INFORMATION AS PER PARA Y OF SCHEDULE III TO COMPANIES ACT, 2013:

ANNEXURE - XLII

- i The Company does not have any immovable property (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) whose title deeds are not held in the name of the company
- ii The Company has not revalued its Property, Plant and Equipment
- iii The Company has not granted loans or advances in the nature of loans are granted to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013.) either severally or jointly with any other person, that are
 - (a) repayable on demand or
 - (b) without specifying any terms or period of repayment
- iv The Company does not have any capital work-in-progress
- v The Company does not have any intangible assets under development .
- vi No proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder
- vii The Company has borrowings from banks or financial institutions on the basis of security of current assets and quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts except as follows.

For MEDICAMEN ORGANICS LTD.

Director

Director



For Medicamen Organics Limited

C.F.O.

For Medicamen Organics Limited

Varsha Bansal
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

For Financial Year 2023-24

Quarter	Name of Bank	Particulars of Securities Provided	Amount as per Books of Account (₹ in Lakhs)	Amount as reported in the quarterly return/ statement (₹ in Lakhs)	Amount of difference (₹ in Lakhs)	Reason for material discrepancies
Q1	Axis Bank	Stock statement	486.51	486.51	-	
Q1	Axis Bank	Book debts	1,156.79	552.36	(604.43)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q2	Axis Bank	Stock statement	607.61	607.61	-	
Q2	Axis Bank	Book debts	1,374.37	540.02	(834.35)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q3	Axis Bank	Stock statement	482.54	482.54	-	
Q3	Axis Bank	Book debts	1,130.20	415.06	(715.14)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q4	Axis Bank	Stock statement	614.26	614.26	-	
Q4	Axis Bank	Book debts	1,670.00	956.22	(713.78)	The Company has inadvertently submitted statements without entries of receipt against such debtors

MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director



For Medicamen Organics Limited
[Signature]

C.F.O.

For Medicamen Organics Limited
[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

For Financial Year 2022-23

Quarter	Name of Bank	Particulars of Securities Provided	Amount as per Books of Account	Amount as reported in the quarterly return/	Amount of difference (₹ in Lakhs)	Reason for material discrepancies
Q1	Axis Bank	Stock statement	458.64	458.64	-	
Q1	Axis Bank	Book debts	729.96	344.11	(385.85)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q2	Axis Bank	Stock statement	459.34	459.34	-	
Q2	Axis Bank	Book debts	516.51	379.42	(137.09)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q3	Axis Bank	Stock statement	578.53	578.53	-	
Q3	Axis Bank	Book debts	691.62	555.06	(136.56)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q4	Axis Bank	Stock statement	613.90	616.20	2.30	
Q4	Axis Bank	Book debts	1,076.82	791.07	(285.75)	The Company has inadvertently submitted statements without entries of receipt against such debtors

FOR MEDICAMEN ORGANICS LTD.

Director

Director

For Medicamen Organics Limited

C.F.O.



For Medicamen Organics Limited

Varsha Bansal
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

For Financial Year 2021-22

Quarter	Name of Bank	Particulars of Securities Provided	Amount as per Books of Account (₹ in Lakhs)	Amount as reported in the quarterly return/ statement (₹ in Lakhs)	Amount of difference (₹ in Lakhs)	Reason for material discrepancies
Q1	Axis Bank	Stock statement	392.74	392.74	-	
Q1	Axis Bank	Book debts	715.36	301.23	(414.13)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q2	Axis Bank	Stock statement	362.69	362.69	-	
Q2	Axis Bank	Book debts	572.76	319.50	(253.26)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q3	Axis Bank	Stock statement	495.69	495.69	-	
Q3	Axis Bank	Book debts	603.26	373.88	(229.38)	The Company has inadvertently submitted statements without entries of receipt against such debtors
Q4	Axis Bank	Stock statement	472.18	471.68	(0.50)	
Q4	Axis Bank	Book debts	624.54	515.59	(108.95)	The Company has inadvertently submitted statements without entries of receipt against such debtors

MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

For Medicamen Organics Limited

[Signature]

C.F.O.



For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

- vi. The company is not declared as willful defaulter by any bank or financial institution or other lender.
- vii. The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.
- viii. The company does not have any investments and hence, compliance with the number of layers prescribed under clause (17) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017 is not applicable.
- ix. Significant Accounting Ratios:

Ratios	For the year ended March 31, 2024	For the year ended March 31, 2023	Variation (%)
(a) Current Ratio	1.25	0.95	31.27%
(b) Debt-Equity Ratio	0.83	1.31	(36.54%)
(c) Debt Service Coverage Ratio	0.38	0.23	65.14%
(d) Return on Equity Ratio	0.20	0.11	74.39%
(e) Inventory turnover ratio	2.11	2.46	(14.57%)
(f) Trade Receivables turnover ratio	1.54	2.60	(29.32%)
(g) Trade payables turnover ratio	2.12	2.27	(6.75%)
(h) Net capital turnover ratio	11.37	14.08	(180.79%)
(i) Net profit ratio	9.51%	4.38%	117.36%
(j) Return on Capital employed	14.50%	9.50%	52.69%
(k) Return on investment	0.00%	0.00%	0.00%

Reasons for Variation more than 25%: Since, comparative period is full financial year, hence, not comparable.

- (a) Current Ratio: Ratio is improved mainly due to decrease in current liabilities whereby company is reducing its utilisation of working capital limits.
- (b) Debt-Equity Ratio: Ratio is decrease mainly due to repayment of borrowings during the year.
- (c) Debt Service Coverage Ratio: Ratio is increased mainly due to increase in profits during the year.
- (d) Return on Equity Ratio: Ratio is improved mainly due to good profits during the year.
- (e) Trade Receivables turnover ratio: Ratio is decreased due to decrease in trade receivable during the year.
- (f) Net capital turnover ratio: Ratio is improved mainly due to increase in revenue during the year.
- (g) Net profit ratio: Ratio is improved mainly due to increase in operating margins during the year.

For Medicamen Organics Limited
Varsha Bansal
Company Secretary

For MEDICAMEN ORGANICS LTD
Sushant
Director

P. S. S. S. S.
Director



For Medicamen Organics Limited
T. S. S. S. S.
C.F.O.

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

Ratios	For the year ended March 31, 2023	For the year ended March 31, 2022	Variation (%)
(a) Current Ratio	0.95	0.88	8.34%
(b) Debt-Equity Ratio	1.31	1.28	2.70%
(c) Debt Service Coverage Ratio	0.23	0.14	65.51%
(d) Return on Equity Ratio	0.11	0.01	795.69%
(e) Inventory turnover ratio	2.46	3.63	(32.14%)
(f) Trade Receivables turnover ratio	2.60	3.05	(14.51%)
(g) Trade payables turnover ratio	2.27	2.67	(14.93%)
(h) Net capital turnover ratio	-	14.08	-
(i) Net profit ratio	4.38%	0.48%	805.34%
(j) Return on Capital employed	9.50%	3.99%	137.88%
(k) Return on investment	0.00%	0.00%	0.00%

Reasons for Variation more than 25%:

- (a) Debt Service Coverage Ratio: Ratio is improved mainly due to good profits during the year.
(b) Return on Equity Ratio : Ratio is improved mainly due to good profits during the year.
(c) Inventory turnover ratio : Ratio is decreased mainly due to decrease in average inventory.
(d) Net capital turnover ratio : Ratio is improved mainly due to good profits during the year.
(e) Net profit ratio: Ratio is improved mainly due to increase in operating margins during the year.
(f) Return on Capital employed: Ratio is improved mainly due to good profits during the year.

For MEDICAMEN ORGANICS LTD.

[Signature]

Director

[Signature]
Director



For Medicamen Organics Limited

[Signature]

C.F.O.

For Medicamen Organics Limited

[Signature]
Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416



ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

Ratios	For the year ended March 31, 2022	For the year ended March 31, 2021	Variation (%)
(a) Current Ratio	0.88	0.86	1.95%
(b) Debt-Equity Ratio	1.28	1.21	5.49%
(c) Debt Service Coverage Ratio	0.14	0.17	(19.88%)
(d) Return on Equity Ratio	0.01	0.04	(67.80%)
(e) Inventory turnover ratio	3.63	4.51	(19.56%)
(f) Trade Receivables turnover ratio	3.05	3.84	(20.66%)
(g) Trade payables turnover ratio	2.67	2.22	20.13%
(h) Net capital turnover ratio	- 9.41	- 8.44	11.47%
(i) Net profit ratio	0.48%	1.19%	(59.38%)
(j) Return on Capital employed	3.99%	5.53%	(27.82%)
(k) Return on investment	0.00%	0.00%	0.00%

Reasons for Variation more than 25%:

- (a) Return on Equity Ratio : Ratio is decreased mainly due to decrease in profits during the year.
(b) Net Profit Ratio: Ratio is decreased mainly due to decrease in operating margins during the year.
(c) Return on Capital Employed : Ratio is decreased mainly due to decrease in profits during the year.

xii. The Company does not have any scheme of arrangements which has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.


For MEDICAMEN ORGANICS LTD

Director

Director



For Medicamen Organics Limited

CFO

For Medicamen Organics Limited


Company Secretary

Medicamen Organics Limited
CIN: U74899DL1995PLC066416

ANNEXURES FORMING PART OF THE RESTATED FINANCIAL STATEMENTS

xiii. A. No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

B. No funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Parties or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

CAPITALISATION STATEMENT AS AT

March 31, 2024

ANNEXURE - XLIII
(₹ In Lakhs)

Particulars	Pre Issue	Post Issue
Borrowings		
Short term debt (A)	1,249.51	-
Long Term Debt (B)	16.14	-
Total debts (C)	1,265.65	-
Shareholders' funds		
Share capital	860.00	-
Reserve and surplus - as Restated	658.40	-
Total shareholders' funds (D)	1,518.40	-
Long term debt / shareholders funds (B/D)	0.01	-
Total debt / shareholders funds (C/D)	0.83	-

Signatures to Annexures Forming Part Of The Restated Financial Statements
For and on behalf of the Board of Directors
For MEDICAMEN ORGANICS LTD.

Bal Krishna Gupta
(Managing Director)

DIN - 00032772

Place : Delhi

Date : 20-05-2024

Director

Director
Ashutosh Gupta
(Director)
DIN - 00039995

C.F.O.
Lalit Gupta
(CFO)

Varsha Bansal
Company Secretary
(Company Secretary)